


Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/601,138
		Filing Date	October 26, 2000
		First Named Inventor	Jens FOGH
		Group Art Unit	1652
		Examiner Name	M. WALICKA
		Attorney Docket Number	FOGH=1
Sheet	1	of	3




OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
df	AA	GRANDCHAMP, B., et al., Tissue-specific expression of porphobilinogen deaminase- Two isoenzymes from a single gene, Eur. J. Biochem., 1987, 162: 105-110	
df	AB	Abstract of GRANDCHAMP, B., et al., Review: molecular pathogenesis of hepatic acute porphyrias, J-Gastroenterol-Hepatol, 1996, 11(11): 1046-1052	
df	AC	ANDERSSON, C., Thesis, Acute Intermittent Porphyria in Northern Sweden A Population-Based Study, 1997, ISBN 91/7191/280/0, 22-23	
df	AD	GRAHAM, et al., Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5, J. Gen. Virol, 1977, 36: 59-74	
df	AE	LEE, et al., Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermitten porphyria, Proc. Natl. Acad. Sci. USA, 1991, 88: 10912-10915	
df	AF	DRANOFF, et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc. Natl. Acad. Sci. USA, 1993, 90: 3539-3543	
df	AG	DANOS, et al., Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges, Proc. Natl. Acad. Sci. USA, 1988, 85: 6460-6464	
df	AH	MOREAU-GAUDRY, et al., Correction of the Enzyme Defect in Cultured Congenital Erythropoietic Porphyria Disease by Retrovirus-Mediated Gene Transfer, Human Gene Therapy, 1995, 6: 13-20	
df	AI	RAICH, et al., Molecular cloning and complete primary sequence of human erythrocyte porphobilinogen deaminase, Nucleic Acid Research, 1986, 14(15): 5955-5698	
df	AJ	TISHLER, et al., High Prevalence of Intermittent Acute Porphyria in a Psychiatric Patient Population, Am. J. Psychiatry, 1985, 142(12): 1430-1436	
df	AK	STRAND, et al. Heme Biosynthesis in Intermittent Acute Porphyria: Decreased Hepatic Conversion of Porphobilinogen to Porphyrins and Increased Delta Aminolevulinic Acid Synthetase Activity, Proceedings of the National Academy of Science, 1970, 67(3): 1315-1320	
df	AL	SASSA, Diagnosis and Therapy of Acute Intermittent Porphyria, Blood Reviews, 1996, 10: 53-58	

Examiner Signature	<i>M. Walicka</i>	Date Considered	Oct. 27, 2001
--------------------	-------------------	-----------------	---------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/601,138
		Filing Date	October 26, 2000
		First Named Inventor	Jens FOGH
		Group Art Unit	1652
		Examiner Name	M. WALICKA
Sheet 2	of 3	Attorney Docket Number	FOGH=1



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>AW</i>	AM	STEPHENS, et al., The bovine papillomavirus genome and its uses as a eukaryotic vector, Biochem. J., 1987, 248: 1-11	
<i>AW</i>	AN	SAIKI, et al., Enzymatic Amplification of β -Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia, Science, 1985, 230: 1350-1354	
<i>AW</i>	AO	MUSTAJOKI, et al., Heme in the Treatment of Porphyrins and Hemotological Disorders, Seminars in Hematology, 1989, 26(1): 1-9	
<i>AW</i>	AP	MILLER, et al., Improved Retroviral Vectors for Gene Transfer and Expression, BioTechniques, 1989, 7(9): 980-990	
<i>AW</i>	AQ	MANIATIS, et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, 440-44	
<i>AW</i>	AR	MANIATIS, et al., Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, 150-160	
<i>AW</i>	AS	LITHNER, et al., Hepatocellular Carcinoma in Patients with Acute Intermittent Porphyrin, Acta. Med. Scand., 1984, 215: 271-274	
<i>AW</i>	AT	JEANS, et al., Mortality in Patients with Acute Intermittent Porphyrin Requiring Hospitalization, American Journal of Medical Genetics, 1996, 65: 269-273	
<i>AW</i>	AU	HERRICK, et al., Controlled Trial of HAEM Arginate in Acute Hepatic Porphyrin, The Lancet, 1989, 1: 1295-1297	
<i>AW</i>	AV	WALDENSTRÖM, Studien Über Porphyrin, Acta. Med. Scand., 1937, Suppl 82: 3-63	XX
<i>AW</i>	AW	YOO, et al., Hydroxymethylbilane Synthase: Complete Genomic Sequence and Amplifiable Polymorphisms in the Human Gene, Genomics, 1993, 15: 21-29	
<i>AW</i>	AX	YEUNG, et al., Early-Onset Chronic Renal Failure as a Complication of Acute Intermittent Porphyrin, Quarterly Journal of Medicine, 1983, 205: 92-98,	
<i>AW</i>	AY	FORMGREN, et al., Effects of Light of Different Wavelengths on the Porphyrin Concentration in the Harderian Gland of the Golden Hamster, Porphyrins in Human Diseases. Reports of the discussion., 1976, 380-384	
<i>AW</i>	AZ	WETTERBERG, A Neuropsychiatric and Genetical Investigation of Acute Intermittent Porphyrin, Scandinavian University Books, 12-15	

Examiner Signature	<i>M. Walicka</i>	Date Considered	<i>Oct. 28, 2001</i>
--------------------	-------------------	-----------------	----------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Use as many sheets as needed

OCT 16 2001

PATENT & TRADEMARK OFFICE

(use as many sheets as necessary)

OCT 16 2001

Sheet 3 of 3

Application Number	09/601,138
Filing Date	October 26, 2000
First Named Inventor	Jens FOGH
Group Art Unit	1652
Examiner Name	M. WALICKA
Attorney Docket Number	FOGH=1

[illegible]

Examiner
Signature

Articles

Date
Considered

Oct. 29, 2001

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.